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Cyclic nucleotide phosphodiesterases (PDEs) regulate all pathways
that use cGMP or cAMP as a second messenger. Five of the 11 PDE
families have regulatory segments containing GAF domains, 3 of
which are known to bind cGMP. In PDE2 binding of cGMP to the
GAF domain causes an activation of the catalytic activity by a
mechanism that apparently is shared even in the adenylyl cyclase
of Anabaena, an organism separated from mouse by 2 billion years
of evolution. The 2.9-Å crystal structure of the mouse PDE2A
regulatory segment reported in this paper reveals that the GAF A
domain functions as a dimerization locus. The GAF B domain shows
a deeply buried cGMP displaying a new cGMP-binding motif and is
the first atomic structure of a physiological cGMP receptor with
bound cGMP. Moreover, this cGMP site is located well away from
the region predicted by previous mutagenesis and structural
genomic approaches.
Cyclic nucleotide phosphodiesterases (PDEs) catalyze thehydrolysis of 3, 5 cyclic nucleotides to the inactive 5
monophosphates. Five of the 11 PDE families contain regulatory
segments consisting of one or two so-called GAF-domain mod-
ules (1), which is one of the largest families of small molecule-
binding regulatory domains. Among PDEs, cGMP is the only
ligand known to bind this domain. The structure of a single GAF
domain from a putative protein from yeast (YKG9) has been
solved recently (2). However, yeast do not make cGMP, nor does
this protein bind cGMP when tested directly (2). cGMP binding
to one of two GAF domains (3) in the photoreceptor PDE6
family provides one mechanism for regulating visual signal
transduction. cGMP also binds to one or more of the GAF
domains of PDE5 (4), the target of the drug, Viagra. The binding
and subsequent phosphorylation of an adjacent domain activates
the catalytic domain of the enzyme (5). In PDE2A, the catalytic
activity is allosterically stimulated by cGMP binding to its GAF
domain (6), an event important for several pathways that PDE2A
has been shown to regulate (7–12). For example, atrial natri-
uretic peptide stimulation of cGMP and subsequent activation of
PDE2A in the adrenal cortex decreases the secretion of aldo-
sterone and, thereby, mediates much of the effect of this
hormone on blood pressure (13). Each PDE2A monomer con-
tains an N-terminal (200 residues) domain of unknown func-
tion, tandem GAF domains (GAF A and GAF B), and a
C-terminal catalytic domain. What seems to be a functionally
very similar tandem set of GAF domains is also present in
Anabaena adenylyl cyclase. This GAF domain has a preference
for cAMP where it functions to confer cAMP activation of
cyclase activity (14). Here, we report the 2.9-Å crystal structure
of the regulatory segment of murine PDE2A, which reveals the
structure of two GAF domains with entirely different functions,
dimerization, and binding of cGMP. Amazingly, this binding
motif and mechanism has apparently been preserved for over 2
billion years in evolution.
Methods and Materials
Crystallization and Data Collection. Crystals were grown at room
temperature in sitting drops by mixing equal volumes of protein
(2–5 mg/ml in 20 mM NaCl10 mM Tris, pH 7.510 mM
DTT0.1 mM EDTA0.1 mM PMSF1g/ml leupeptin1g/ml
pepstatin A2 mM Na 3, 5 cGMP) and reservoir (16–26% 1,4
butanediol100 mM sodium acetate, pH 5.0), with 140 mM
-mercaptoethanol added to the reservoir after setting up the
drop. The space group is F222, with a  134.2 Å, b  136.2 Å,
and c  149.1 Å with one monomer in the asymmetric unit, 70%
solvent content, and Vm  4.1 Å3Da. Because E. coli does not
have a guanylyl cyclase, the bound cGMP is not likely to be
endogenous. Crystals were square plates up to 600 microns on a
side and up to 100 microns thick. Crystals were flash-cooled out
of the drop in liquid nitrogen and kept at 100 K during data
collection at beamline 19-BM (Advanced Photon Source, Ar-
gonne National Laboratory, Argonne, IL), for multiple anom-
alous dispersion data, and beamline 5.0.2 (Advanced Light
Source, Lawrence Berkeley National Laboratory, Berkeley, CA)
for native data. Data sets were processed with HKL2000.
Structure Determination and Refinement. Three of the six potential
selenium sites were determined, and phasing was achieved by
using the program SOLVE with a 3.1 Å SeMet data set (15). The
three C-terminal methionines seemed to be disordered. After
solvent flattening with RESOLVE (16), side-chain density was well
defined for many residues in the 3.1-Å RESOLVE map. A model
was built manually by using the O program. The model was
refined by using a 2.86-Å native Met data set with the program
CNS by using restrained individual B factors (17). Residues
207–214 and 556–566, followed by the histidine tag LE(H6),
were completely disordered and not included in the model.
Results and Discussion
Tertiary and Quaternary Structure. The crystal structure of the
PDE2A regulatory segment was determined at 2.9-Å resolution,
with one monomer per asymmetric unit in space group F222.
The quality of the structure is reflected in low R-work and R-free
values of 22.1 and 26.9%, respectively, with good stereochemical
parameters (see Table 1, which is published as supporting
information on the PNAS web site, www.pnas.org). Residues
215–555 were all well defined in the electron density map. The
first GAF domain (residues 215–366, GAF A) is followed by a
‘‘connecting helix’’ (residues 367–398), a short linker (residues
399–402), and the second GAF domain (GAF B, residues
403–555). A single subunit extends over 100 Å in its longest
dimension, with the centers of the two GAF domains in the same
subunit separated by about 65 Å. Two PDE2A regulatory
segments form a dimer related by twofold symmetry that is
parallel with the crystallographic c axis (Fig. 1a). The monomers
cross at the connecting helix. The dimer interface is made up of
helices and loops from GAF A and the first seven turns of the
connecting helix, burying a total of 2,814 Å2 of solvent-accessible
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surface. The monomers diverge after Cys-386 because of a bend
that causes the last three turns of the connecting helices to move
further and further away from each other, thus making the
centers of the two GAF B domains 65 Å apart. The dimer
observed in the crystals is consistent with earlier biochemical
data for the PDE2A holoenzyme that suggests the N-terminal
region is responsible for dimerization (18).
The two interacting GAF A domains alone bury 1,338 Å2 of
solvent accessible surface. Although YKG9 also forms a dimer
(2), the subunit–subunit interface of the yeast protein is entirely
different. In PDE2A, several hydrophobic residues are involved
in the dimer interface, including L223 of helix 1 which inserts
into a hydrophobic pocket formed by I222, L223, C226, all
from helix 1, and Y365 from the kink between 5 and the
connecting helix. D219 on 1 seals the pocket from the solvent.
The 1-2 loop packs against the 5-6 loop. In addition, the
interaction between the connecting helices buries 1,476 Å2,
involving residues from one side of the first seven turns, with
residues V369, S372, F376, E379, K383, C386, and L390 of both
helices most deeply involved in the contacts. C386 is near the end
of the helix–helix interface and forms a disulfide bridge with its
symmetry partner in our structure even though all purification
and crystallization steps were carried out in the presence of high
concentrations of reducing agent. C386 is not conserved in the
other PDE families, and it is not known whether this disulfide is
present in the native enzyme, although recently other cyclic
nucleotide-binding molecules have been reported to be disulfide
linked in the cell (19). Eliminating the disulfide bond with the
Fig. 1. (a) Two views of the structure of the regulatory segment of mouse PDE2A. Each PDE2A subunit contains a GAF A and a GAF B domain. The GAF A domain
and seven turns of the connecting helices form a dimer interface. The two GAF B domains are far apart and contain the cGMP-binding sites. (Upper) View showing
the dimer interface of the regulatory segment. (Lower) View 70° rotated with respect to A showing the Y-shape and the disulfide at C386 most clearly. cGMP
is shown in red. The overall dimensions of the regulatory segment dimer are 105  92  71 Å. (b and c) Stereo images comparing GAF B with GAF A or YKG9.
The C positions of the 11 residues that contact cGMP are shown as red spheres. (b) PDE2A GAF B (blue, with bound cGMP) and PDE2A GAF A (green) is shown
after least-squares superposition of C positions. There are significant main-chain differences in the GAF pocket. Note that the main chain from the N terminus
of helix 4 in GAF A clashes with the guanine ring of cGMP in GAF B. (c) Superposition of the C positions of PDE2A GAF B onto YKG9. Note that the loop in
GAF B that contacts the guanine ring through D438 and F439 is turned away in YKG9. Helix 4 in GAF B is another significant difference between GAF B and
YKG9. The conserved NKFDE motif predicted in early studies to be involved in cGMP binding (29) is shown in gray in GAF B. The five conserved residues in this
loop (N, K, F, D, and E) are indicated by black spheres. The first four residues from the YKG9 model (monomer A, residues 4–7) point away from the domain and
have been deleted for clarity.
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mutation C386S has no or little effect on conformation (see
Supporting Text, which is published as supporting information on
the PNAS web site), showing its presence or absence has no
effect on the overall structure of the dimer, including the
splaying of GAF B and B.
GAF A and GAF B share many similar structural features but
also have distinct conformational differences as well (Fig. 1b and
Fig. 2 b and c). GAF A and GAF B both have an anti-parallel 
sheet with strand order 3-2-1-6-5-4. GAF A and B differ in the
number of helices preceding the sheet, with two helices, 1 and 2,
preceding the first  strand in GAF A, whereas helix 1 is not
present in GAF B. In GAF A, helices 1, 2, and 5, plus the first
two turns of the connecting helix, form a helix bundle with helices
2 and 5 packing against one side of the  sheet, as in GAF B.
Overall, 130 equivalent C atoms from the GAF A and GAF B
domains can be superimposed with an rms deviation of 3.0 Å and
a sequence identity of 19%. Interestingly, the overall folds of the
three GAF domains with known structure are very similar (Fig. 2),
with the yeast variant having an additional N-terminal helix com-
pared with the PDE2 GAF A. Yeast YKG9 (monomer A, PDB
1F5M) is distantly related to PDE2A GAF A, with 136 C atoms
superimposing within 4.0 Å and a sequence identity of 10%, and to
GAF B, with 130 equivalent C atoms which superimpose within
an rms deviation of 3.3 Å and a sequence identity of 16%.
cGMP Binding by the GAF B Domain. The electron density for cGMP
in the GAF B domain is unambiguous, with the highest density
indicating the position of the phosphoryl moiety (Fig. 3A). cGMP
is bound in the GAF B pocket in an anti-conformation, as predicted
by earlier analog studies (20). Unexpectedly, the cyclic phosphate
is in the energetically unfavorable boat conformation. The cGMP
is entirely buried with 485 Å2 out of its solvent-accessible surface of
489 Å2 excluded from contact with solvent by the protein. Three
waters bound to cGMP also are buried. Only the cGMP C2 amino
group is visible from outside the protein. Therefore, GAF B must
be in or proceed through a more open conformation before binding
cGMP.
An important residue for cGMP binding by GAF B is D439,
which is engaged in both a side chain and backbone contact with the
guanine base (Fig. 3 B and C). OD1 of D439 makes a 2.6 Å H-bond
with the protonated N1 of guanine, and the backbone amide
hydrogen bonds to the carbonyl oxygen O6. Two contacts with N3
and the amino group N2 in guanine are mediated by 2.6-Å and
2.8-Å hydrogen bonds to water HOH1. This water in turn makes a
2.8-Å contact to the OG of T488 and longer 3.2 to 3.3-Å contacts
to OD1 of D485 and the backbone carbonyl of V484. The last
guanine hydrogen bond is S424, whose OG1 is 2.7 Å from the
unprotonated N7. There are no contacts to the remaining polar
guanine atom, N9. The side-chain F438 is base stacked with the
guanine ring. Although F438 is in Van der Waals contact, F490 is
the nearest aromatic residue on the other side of the ring but
probably too far (5 Å) away to interact with it.
In the ribose ring, the 2 OH forms H-bonds with the side
chain of T492 and water HOH2. The latter is itself bound by the
backbone amide of D485 and the carbonyl of Y481. E512, the
only buried acidic side chain in the binding pocket, interacts via
its side chain with water HOH3, which itself makes a 2.6-Å
contact with the 3 O. This water also contacts the backbone
amide of A459. The side chain of V484 is in close proximity to
several ribose atoms, including C1, C4, C5, and O4.
Our structure of GAF B allows the first opportunity to see how
the cyclic phosphate of cGMP is interacting with a physiological
receptor (Fig. 3 B and C). The 3, 5 cyclic phosphate is bound
by two backbone amides and also interacts with a helix dipole.
The two-turn helix A3, comprising residues 457 to 465, points to
the phosphate group with its N-terminal end. The nonbridging
O2A forms a short 2.5-Å H-bond to the amide nitrogen of I458.
The O1A of the cyclized phosphate makes a 3.0-Å H-bond to the
backbone nitrogen of Y481. The bridging 3 O interacts with
the water HOH3, whereas the 5 O is not engaged in any
interaction with a water or protein atom. The contacts recog-
nizing the 3, 5 cyclic phosphate group, the most distinctive
feature of this nucleotide second messenger, are, therefore,
mainly realized by the specific backbone conformation of this
GAF domain. The importance of backbone nitrogens to binding
explains why no consensus residues involved in cyclic nucleotide
binding were recognized previously by comparative sequence
alignment approaches.
The ability of PDE2A to discriminate between cGMP and
cAMP seems to be due, at least in part, to interactions with
Asp-439 (Fig. 3C). Asp-439 can provide positive specificity
determinants for cGMP but probable negative interactions with
cAMP. Its main-chain NH forms a 2.8-Å hydrogen bond with O6
of the guanine base, which, if adopting the same position as
observed in our structure, would be incompatible with the NH2
group of cAMP. In addition, its carboxylate side chain forms
Fig. 2. Comparison of GAF domains. Topology diagrams of YKG9 (a), PDE 2A
GAF A (b), and GAF B (c). In GAF B, the helix 3, whose dipole interacts with the
bound cGMP phosphate moiety, is indicated in blue. *, indicates 11 contacts to
cGMP. Helix 4 in GAF B, which provides a large number of contacts, is indicated
in orange. The conserved NKFDE motif of GAF A and B (see text) is indicated in
green. In YKG9, the additional N-terminal helix is indicated in purple. Arrows
indicate -strands, and helices indicate -helices.
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a 2.6-Å hydrogen bond with the protonated N1 of the guanine,
which should be lost with the unprotonated N1 in the adenine of
cAMP. It seems likely that the first of these two discriminating
factors is more important than the second, because Asp-439 is
quite exposed to the solvent (Fig. 3B). Therefore, a change in its
1 dihedral angle could move the side chain into other positions
without any clashes with protein atoms but still be fully hydrated
by bulk solvent. As a first test of this model, we measured cGMP
and cAMP binding by competition using the Millipore filtration
method (Fig. 3D). Wild-type protein shows an IC50 for cGMP
of 26 nM and 300 nM for cAMP. This approximately 12-fold
difference is consistent with the model discussed above and with
previous binding studies on the holoenzyme. Clearly, mutagen-
esis data will be necessary to test these predictions rigorously.
Somewhat surprisingly, the IC50 for cGMP (26 nM) is at
least 4 lower than reported for cGMP binding to the bovine
PDE2A holoenzyme (21, 22) and more than 15-fold lower than
the apparent Ka for activation of enzymatic activity (23–25). It
seems possible that this difference is because of the absence of
the catalytic domain in our fragment, although a species differ-
ence or homomeric subunit interaction cannot be ruled out.
cGMP binding to the regulatory domain of PDE2A stimulates
Fig. 3. cGMP binding by PDE2A. (A) Electron density in a Sigma A-weighted omit map contoured at the 1.0  level shown together with cGMP bound to the
GAF B domain of PDE2A. The density at the phosphate is 5 . Also shown is the critical Asp D439 that interacts with the guanine base with both its side-chain
carboxylate and main-chain amino groups. This figure was prepared with BOBSCRIPT (31) and rendered with RASTER3D (32). (B) Close-up view of the cGMP-binding
site in GAF B. Shown are six side chains that make hydrogen bonds to the cGMP, one that stacks with the guanine ring, and two that make backbone amide
contacts. Helix 4 and strand 3 are depicted as coils for visibility of the cGMP. This figure was made with MOLSCRIPT (31) and RASTER3D (32). (C) Diagram showing
all of the close interactions between cGMP and GAF B. The diagram was produced with LIGPLOT (33). The general features of cGMP binding in the GAF B structure
are consistent with many of the predictions made from binding studies of PDE2 and PDE6 with cyclic nucleotide analogues. These studies suggested that cGMP
would be bound in the anti-conformation, that contacts are made to C6, N1, and C2 amino group of the guanine ring and 2O of the ribose ring, and that there
are similar or identical types of contacts to the exocyclic oxygens (21, 26, 34). (D) cGMP and cAMP competition binding curves [against (3H)cGMP] for the wild-type
regulatory segment of mouse PDE2A. A nitrocellulose filter-binding assay was used (18). Protein concentration was 0.6 nM.
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the Vmax by 10-fold (23, 25–27). By the principle of microscopic
reversibility, it could be expected that binding of a ligand to the
catalytic site of the holoenzyme might affect the affinity at the
GAF B site. That is, because cGMP binding to GAF B results in
activation of an inactive catalytic domain, it would not be
unexpected that the presence of the catalytic domain could
decrease the affinity of cGMP for its binding site. Such an
interaction could allow the holoenzyme to bind cGMP in the
physiological concentration range.
Consensus Sequences Are Not Directly Involved in cGMP Binding. The
loop between strand 6 and helix 5 at the C-terminal end of the
chain contains a motif N[KR]X(5–14)FX(3)DE, the ‘‘NKFDE’’ motif,
which is highly conserved in essentially all PDE GAF domains and
has been implicated by mutagenesis experiments to be involved in
cGMP binding (28, 29). The sequence of this motif resembles the
GTP-binding NKxD motif in GTP-binding proteins (29). However,
the NKFDE loop residues of GAF B are not in contact with the
cGMP and, in fact, reside at the other side of the-sheet of the GAF
domain, far from the cGMP-binding site (Fig. 1b). How the
mutations in N276, K277, and D289 affect cGMP binding in
PDE5A GAF A (29) and why the NKFDE motif is so well
conserved deserves further investigation. Because of sequence
conservation, this motif was predicted as the cGMP-binding site
based on homology modeling from YKG9 (2). However, the GAF
B domain of PDE2A organizes the residues between -strands 4
and 5 into the 4 helix, whereas YKG9 does not. Because this helix
is intimately involved in cGMP binding, it is clear why predictions
about the location of the cGMP-binding site based on the YKG9
structure were difficult.
The cGMP-Binding Motif in PDEs. It was of interest to see if the 11
cGMP-binding contacting residues, i.e., S424, F438, D439, I458,
A459, Y481, V484, D485, T488, T492, and E512, are conserved in
Fig. 4. Sequence alignment of GAF A and B domains from mouse PDE2A, human PDE2A, human PDE5A, and human PDE6A, -B, and -C. The secondary structure
elements from PDE2A GAF A and B are indicated at the top line. Absolutely conserved residues are indicated in purple, and conserved residues are indicated in
blue. Colored columns indicate the following contacts to cGMP: green, polar side chains; gray, hydrophobic side chains; pink, backbone amides. Yellow columns
are residues in the NKFDE motif (see text). The 11 contact residues with cGMP are indicated with double underscored numbers 1–11. h, human; m, mouse; 2A,
PDE2A; GA, GAF A; GB, GAF B.
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the two other PDE families, PDE5 and PDE6, that are confirmed
to have cGMP-binding regulatory segments. Aside from our crys-
tallographic investigation of PDE2A GAF B, the only other isolated
PDE GAF domain for which cGMP binding has been experimen-
tally confirmed is PDE5 GAF A (2, 30). The GAF A domain of
PDE5A has the highest sequence identity (48%) with the PDE 2A
GAF B domain. Moreover, all cGMP-binding side chains in
PDE2A GAF B are identical in PDE5A GAF A except for the
phosphate-binding E512, which is a Gln (Fig. 4), clearly allowing
hydrogen bonding through water HOH3 with the 3 O of the
ribose-phosphate bridge (Fig. 3C). The high degree of identity,
along with a conservative substitution, is consistent with the ex-
perimental observation that the PDE5A regulatory segment binds
cGMP. Therefore, based on the sequences of PDE2A GAF B and
PDE5A GAF A, the cGMP-binding motif is
SX13–18FDX18 –22IAX21	YN
X2VDX2TX3TX19[EQ]
1 2,3 4,5 6 7,8 9 10 11 .
Eight of these 11 residues contact cGMP through side chains, three
through waters. Six of the 11 contact cGMP through main chain
amide or carbonyls, making 7 contacts in total, of which 4 are
mediated by waters. Depending on the species, the motif spans
approximately 90 residues that are contributed by five different
secondary structure elements, of which 4 provides four contact
residues (Fig. 2c). Inspection of the PDE2A GAF A and PDE5A
GAF B sequences reveals many motif substitutions that would seem
to be incompatible with binding of cGMP (Fig. 4).
The three photoreceptor phosphodiesterases, PDE6A, -6B, and
-6C, are the members of the other PDE family for which binding of
cGMP to the regulatory segment has been well documented (3, 20).
The motif derived above suggests that the cGMP-binding domain
of PDE6 will be GAF A. Of eight contacting side chains, four are
identical to that of the motif (Fig. 4, positions 1, 8, 9, 10). The other
four side chains (positions 2, 3, 7, 11) are conserved or should be
tolerated. Compared with GAF A, the GAF B sequences of the
PDE6 family members deviate much more from the cGMP-binding
motif. Hence, one arrives at the intriguing conclusion that despite
an overall similarity in domain organization of this group of PDEs,
in PDE2A it is GAF B which binds cGMP, whereas in PDE5A, it
is GAF A. Moreover, it is likely to be GAF A for PDE6 family
members—exactly the opposite domain as in PDE2A. In other
GAF-PDE families (PDE10, 11), the motif is perfectly conserved
only in PDE11A GAF A (data not shown), with a conservative
isoleucine substitution at position 7, but careful binding studies have
not been reported for either family. Clearly, direct binding studies
will be required to confirm these predictions.
Finally, it has recently been reported that the cGMP-binding
GAF domains of PDE2 can be swapped with the cAMP-binding
GAF domains of Anabaena adenylyl cyclase and still allow reten-
tion of adenylyl cyclase activity (14). Moreover, this change allows
cGMP rather than cAMP to stimulate cAMP synthesis by the
enzyme. This data strongly suggests that the basic functional
features of the GAF domain structure reported in this paper have
been adapted with little change to function as a cyclic nucleotide
switch that has been conserved over perhaps 2 billion years of
evolution.
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